BridgeBio Pharma Inc’s recent filing unveils that its Chief Executive Officer Kumar Neil unloaded Company’s shares for reported $1.72 million on Nov 20 ’25. In the deal valued at $65.84 per share,26,156 shares were sold. As a result of this transaction, Kumar Neil now holds 228,776 shares worth roughly $16.24 million.
Then, NEIL KUMAR bought 26,156 shares, generating $1,714,264 in total proceeds.
Before that, Lo Andrew sold 55,000 shares. BridgeBio Pharma Inc shares valued at $3,613,069 were divested by the Director at a price of $65.69 per share. As a result of the transaction, Lo Andrew now holds 50,583 shares, worth roughly $3.59 million.
A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in late July with a ‘”a Buy”‘ rating. Jefferies began covering BBIO with “Buy” recommendation on July 14, 2025. Oppenheimer revised its rating on July 09, 2025. It rated BBIO as “an Outperform” which previously was an “a Perform”.
Price Performance Review of BBIO
On Monday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock jump 4.23% to $70.99. Over the last five days, the stock has gained 6.11%. BridgeBio Pharma Inc shares have risen nearly 208.12% since the year began. Nevertheless, the stocks have risen 158.71% over the past one year. While a 52-week high of $69.48 was reached on 11/24/25, a 52-week low of $22.47 was recorded on 01/02/25.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 68.79, which if violated will result in even more drops to 66.60. On the upside, there is a resistance level at 72.31. A further resistance level may holdings at 73.63.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2025-10-31, growing by 2.08 million shares to a total of 19.57 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 17.49 million shares. There was a rise of 10.63%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 17, 2025 when Wolfe Research began covering the stock and recommended ‘”an Outperform”‘ rating along with a $49 price target.
